Literature DB >> 24719899

Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.

Jonathan Samuel Zipursky, Tivon I Sidorsky, Carolyn A Freedman, Misha N Sidorsky, Kathryn B Kirkland.   

Abstract

BACKGROUND: Fecal microbiota transplantation (FMT) is a safe and effective, yet infrequently used therapy for recurrent Clostridium difficile infection (CDI).
OBJECTIVE: To characterize barriers to FMT adoption by surveying physicians about their experiences and attitudes toward the use of FMT.
METHODS: An electronic survey was distributed to physicians to assess their experience with CDI and attitudes toward FMT.
RESULTS: A total of 139 surveys were sent and 135 were completed, yielding a response rate of 97%. Twenty-five (20%) physicians had treated a patient with FMT, 10 (8%) offered to treat with FMT, nine (7%) referred a patient to receive FMT, and 83 (65%) had neither offered nor referred a patient for FMT. Physicians who had experience with FMT (performed, offered or referred) were more likely to be male, an infectious diseases specialist, >40 years of age, fellowship trained and practicing in an urban setting. The most common reasons for not offering or referring a patient for FMT were: not having 'the right clinical situation' (33%); the belief that patients would find it too unappealing (24%); and institutional or logistical barriers (23%). Only 8% of physicians predicted that the majority of patients would opt for FMT if given the option. Physicians predicted that patients would find all aspects of the FMT process more unappealing than they would as providers.
CONCLUSIONS: Physicians have limited experience with FMT despite having treated patients with multiple recurrent CDIs. There is a clear discordance between physician beliefs about FMT and patient willingness to accept FMT as a treatment for recurrent CDI.

Entities:  

Mesh:

Year:  2014        PMID: 24719899      PMCID: PMC4072236          DOI: 10.1155/2014/403828

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  21 in total

Review 1.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

2.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

Review 3.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

4.  Fecal microbiota transplantation--an old therapy comes of age.

Authors:  Ciarán P Kelly
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

5.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

7.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.

Authors:  Jacques Pépin; Sophie Routhier; Sandra Gagnon; Isabel Brazeau
Journal:  Clin Infect Dis       Date:  2006-02-07       Impact factor: 9.079

8.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.

Authors:  Denise Gravel; Mark Miller; Andrew Simor; Geoffrey Taylor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly; David Boyd; Michael Mulvey
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

9.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

Authors:  L Clifford McDonald; Maria Owings; Daniel B Jernigan
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

10.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

View more
  16 in total

Review 1.  Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Authors:  Ryan Eliott; Pratik Panchal; Shrish Budree; Alex Scheeler; Geraldine Medina; Monica Seng; Wing Fei Wong; Thomas Mitchell; Zain Kassam; Jessica R Allegretti; Majdi Osman
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 2.  Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.

Authors:  Colleen R Kelly; Stacy Kahn; Purna Kashyap; Loren Laine; David Rubin; Ashish Atreja; Thomas Moore; Gary Wu
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

Review 3.  Fecal microbiota transplantation for the treatment of Clostridium difficile infection.

Authors:  Krishna Rao; Nasia Safdar
Journal:  J Hosp Med       Date:  2015-09-07       Impact factor: 2.960

4.  Chinese physicians' perceptions of fecal microbiota transplantation.

Authors:  Rong-Rong Ren; Gang Sun; Yun-Sheng Yang; Li-Hua Peng; Shu-Fang Wang; Xiao-Hong Shi; Jing-Quan Zhao; Yong-Ling Ban; Fei Pan; Xue-Hong Wang; Wei Lu; Jian-Lin Ren; Ying Song; Jiang-Bin Wang; Qi-Ming Lu; Wen-Yuan Bai; Xiao-Ping Wu; Zi-Kai Wang; Xiao-Mei Zhang; Ye Chen
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

5.  Low awareness but positive attitudes toward fecal transplantation in Ontario physicians.

Authors:  Madison Dennis; Mary Jane Salpeter; Susy Hota
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jan-Feb       Impact factor: 2.471

6.  Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Authors:  Lauren Lapointe-Shaw; Kim L Tran; Peter C Coyte; Rebecca L Hancock-Howard; Jeff Powis; Susan M Poutanen; Susy Hota
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

7.  Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance.

Authors:  Leslie Park; Anjali Mone; Jennifer C Price; Demetrios Tzimas; Jacqueline Hirsh; Michael A Poles; Lisa Malter; Lea Ann Chen
Journal:  Ann Gastroenterol       Date:  2016-10-20

Review 8.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 9.  Fecal microbiota transplantation: current clinical efficacy and future prospects.

Authors:  Kathryn A Bowman; Elizabeth K Broussard; Christina M Surawicz
Journal:  Clin Exp Gastroenterol       Date:  2015-10-23

10.  How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study.

Authors:  Yonghui Ma; Jinqiu Yang; Bota Cui; Hongzhi Xu; Chuanxing Xiao; Faming Zhang
Journal:  BMC Med Ethics       Date:  2017-05-31       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.